Completed NA INTERVENTIONAL 1-arm NCT00167167

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions AML Leukemia, Lymphocytic, Acute Leukemia, Myeloid, Chronic MDS

Updated 8 times since 2017 Last updated: Nov 27, 2017 Started: Dec 31, 1995 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on AML and Leukemia, Lymphocytic, Acute, this trial is completed. The trial is conducted by Masonic Cancer Center, University of Minnesota and has accumulated 8 data snapshots since 1995. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 3 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed NA
Feb 2017 — Dec 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Dec 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Masonic Cancer Center, University of Minnesota

Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States